Polyplus-transfection® further expands transfection reagent portfolio for Cell and Gene therapy GMP production
Strasbourg, December 13th 2018 – Polyplus-transfection® SA, a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics, today announces the launch of PEIpro®-GMP, a transfection reagent designed for the clinical and commercial lentivirus and adeno-associated virus (AAV) production of cell & gene therapies.
Polyplus-transfection has released PEIpro-GMP to provide a solution for the cell and gene therapy industry faced with tightening regulations. The increase in regulatory requirements include the use of reagents as raw material in the production of viruses for clinical trials, specifically mandating higher levels of quality compliance at earlier stages of clinical development.
As a result, industrial viral vector production for cell & gene therapy has to increase in quality, with the essential use of cGMP compliant raw materials such as plasmids. Polyplus-transfection’s latest product, PEIpro-GMP, has been designed as the highest quality grade transfection reagent available on the market that is compliant with all cGMP viral vector manufacturing requirements.